RGBP (Regen BioPharma) Cyclically Adjusted PB Ratio: (As of Jul. 06, 2026)


What is Regen BioPharma Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Regen BioPharma  (OTCPK:RGBP) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Regen BioPharma Cyclically Adjusted PB Ratio Related Terms


Regen BioPharma Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Regen BioPharma's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regen BioPharma Cyclically Adjusted PB Ratio Chart

Regen BioPharma Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Regen BioPharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

RGBP vs SIGY, ENDV, CNBX: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Regen BioPharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regen BioPharma Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regen BioPharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Regen BioPharma's Cyclically Adjusted PB Ratio falls into.



Regen BioPharma Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Regen BioPharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Regen BioPharma's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book=Book Value per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.015/330.2130*330.2130
=-0.015

Current CPI (Mar. 2026) = 330.2130.

Regen BioPharma Quarterly Data

Book Value per Share CPI Adj_Book
201606 -2.872 241.018 -3.935
201609 -3.231 241.428 -4.419
201612 -0.881 241.432 -1.205
201703 -8.049 243.801 -10.902
201706 -21.935 244.955 -29.570
201709 -28.323 246.819 -37.893
201712 -40.092 246.524 -53.702
201803 -43.837 249.554 -58.006
201806 -40.533 251.989 -53.116
201809 -38.083 252.439 -49.816
201812 -25.839 251.233 -33.962
201903 -17.583 254.202 -22.841
201906 -18.583 256.143 -23.957
201909 -13.685 256.759 -17.600
201912 -4.081 256.974 -5.244
202003 -5.518 258.115 -7.059
202006 -4.018 257.797 -5.147
202009 -3.448 260.280 -4.374
202012 -1.868 260.474 -2.368
202103 -1.308 264.877 -1.631
202106 -2.100 271.696 -2.552
202109 -2.333 274.310 -2.808
202112 -1.611 278.802 -1.908
202203 -12.575 287.504 -14.443
202206 -1.280 296.311 -1.426
202209 -1.205 296.808 -1.341
202212 -0.735 296.797 -0.818
202303 -0.729 301.836 -0.798
202306 -0.744 305.109 -0.805
202309 -0.728 307.789 -0.781
202312 -0.699 306.746 -0.752
202403 -0.629 312.332 -0.665
202406 -0.590 314.175 -0.620
202409 -0.496 315.301 -0.519
202412 -0.264 315.605 -0.276
202503 -0.264 319.799 -0.273
202506 -0.184 322.561 -0.188
202509 -0.160 324.800 -0.163
202512 -0.061 324.054 -0.062
202603 -0.015 330.213 -0.015

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Regen BioPharma Business Description

Other Exchanges RGBPP.PFD:USA
Address 8697 La Mesa Boulevard, Suite C, La Mesa, CA, USA, 91942
Regen BioPharma Inc is a USA-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II are cellular therapies designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.